Written question asked by Julian Sturdy (Conservative) on Tuesday, 9 March 2021, in the House of Commons. It was due for an answer on Thursday, 11 March 2021. It was answered by Nadine Dorries (Conservative) on Wednesday, 17 March 2021 on behalf of the Department of Health and Social Care.
Coronavirus: Ivermectin
- Question
-
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of Ivermectin as a prophylactic and treatment for covid-19; and what plans his Department has to use Ivermectin to treat covid-19.
- Answer
-
Currently, ivermectin for oral use is not a licensed human medicine in the United Kingdom. For ivermectin to be granted a marketing authorisation in the UK, an application must be submitted to the Medicines and Healthcare products Regulatory Agency (MHRA) for review. The MHRA has processes in place to expedite such an application, and assess this for quality, efficacy and safety.
The MHRA is aware that ivermectin, administered orally, is being studied for safety and efficacy in numerous clinical trials worldwide and is used in some countries in the treatment of COVID-19. While some studies have reported findings, other large studies are still on-going.
Secondary information
- Type
- Written question
- Reference
- 165519
- Session
- 2019-21
- Subjects
- Disease control Coronavirus Ivermectin
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2021-03-17 16:41:38 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2019-21/165519
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2019-21/165519
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2019-21/165519